Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
Weight management is one of the most studied areas in all of medicine, yet one of the most challenging in clinical practice. The past five years have witnessed a paradigm shift: the recognition that obesity is a chronic metabolic disease — not a failure of willpower — and that pharmacological support, including peptide-based therapies, can play an important role in long-term management. This article provides a clinical overview of the evidence for peptide-assisted weight management, the populations studied, and the clinical framework within which these therapies are prescribed.
The Metabolic Disease Model of Obesity
Modern obesity medicine frames excess adiposity as the result of dysregulation in energy homeostasis — involving appetite-regulating hormones (leptin, ghrelin, GLP-1, PYY), set-point mechanisms in the hypothalamus, and metabolic adaptations that resist weight loss and promote weight regain. This framework underpins why short-term caloric restriction rarely produces lasting results and why pharmacological interventions targeting these regulatory systems have demonstrated meaningful clinical benefit.
This landmark study demonstrated that after diet-induced weight loss, compensatory hormonal changes persist for at least 12 months: ghrelin rises, PYY falls, and GLP-1 is suppressed — all driving increased hunger and reduced satiety. This work provided the physiological basis for why GLP-1 receptor agonists, which counteract several of these compensatory mechanisms, are particularly relevant to sustained weight management.
Peptide Therapies With Weight Loss Evidence
Semaglutide 2.4 mg (Wegovy)
As detailed in our dedicated semaglutide article, the STEP trial program demonstrated mean weight losses of 9.6–17.4% across different patient populations, with cardiovascular benefit confirmed in the SELECT trial. FDA-approved for chronic weight management.
Tirzepatide 15 mg (Zepbound)
The SURMOUNT trials demonstrated mean weight losses up to 20.9% — approaching the outcomes seen with bariatric surgery in some patients. FDA-approved for chronic weight management in 2023.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (hGH 176-191) that was studied for anti-obesity effects in the 1990s and 2000s by Metabolic Pharmaceuticals. Preclinical studies found lipolytic effects without the insulin-desensitizing or growth-promoting properties of full-length GH. A phase 2 trial in obese patients found modest weight loss compared to placebo, but the trial did not achieve its primary endpoints at higher effect sizes, and commercial development was discontinued. AOD-9604 received GRAS (Generally Recognized as Safe) designation from the FDA for use as a food ingredient.
The Importance of Comprehensive Management
Peptide-assisted weight loss programs at responsible telehealth practices are embedded in a broader clinical framework: dietary assessment, physical activity guidance, behavioral support, regular monitoring, and metabolic lab review. Peptides are not used in isolation, and treatment appropriateness is determined by a licensed physician for each individual patient based on their medical history, BMI, comorbidities, medications, and goals.
As data from the STEP 4 trial illustrate, weight regain following discontinuation of GLP-1 therapy is common — reinforcing the chronic-disease model and the importance of long-term management strategies that extend beyond the peptide prescription itself.
References
- Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-604.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss. JAMA. 2021;325(14):1414-1425.
- Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. J Endocrinol. 2001;168(1):35-43.